Inventor · disambiguated record
Masatomo Kato
Also filed as: KATO MASATOMO
17 granted patents·9 pending applications·17 citations·filing 2002–2022
90Inventor score
Files withSANTEN PHARMACEUTICAL CO LTD13MATSUDA MAMORU7KATO MASATOMO3SINGAPORE HEALTH SERV PTE LTD1UNIV FUKUI1
Top patents by PatentIndex Score
26 records- 0193US11419880B2Ursodeoxycholic acid-containing agent for treating or preventing presbyopiaSANTEN PHARMACEUTICAL CO LTD·Filed 2021·Granted Aug 23, 2022·2 cites·9 claims
- 0278US8017775B21-2-dihydroquinoline derivative having glucocorticoid receptor binding activitySANTEN PHARMACEUTICAL CO LTD·Filed 2006·Granted Sep 13, 2011·3 cites·35 claims
- 0377US8551991B21,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activityMATSUDA MAMORU·Filed 2007·Granted Oct 8, 2013·3 cites·17 claims
- 0477US8193187B21,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activityMATSUDA MAMORU·Filed 2008·Granted Jun 5, 2012·3 cites·15 claims
- 0574US8008498B21,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituentsSANTEN PHARMACEUTICAL CO LTD·Filed 2007·Granted Aug 30, 2011·1 cites·8 claims
- 0672US2023040386A1Ursodeoxycholic acid-containing agent for treating or preventing presbyopiaSANTEN PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0770US8664221B2Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituentKATO MASATOMO·Filed 2009·Granted Mar 4, 2014·2 cites·8 claims
- 0869US2022072012A1Ursodeoxycholic acid-containing agent for treating or preventing presbyopiaSANTEN PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 0968US8569493B2Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compoundMATSUDA MAMORU·Filed 2012·Granted Oct 29, 2013·1 cites·12 claims
- 1066US8426406B2Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy groupKATO MASATOMO·Filed 2009·Granted Apr 23, 2013·2 cites·17 claims
- 1164US8008497B21,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituentsSANTEN PHARMACEUTICAL CO LTD·Filed 2007·Granted Aug 30, 2011·0 cites·9 claims
- 1264US8008496B21,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituentsSANTEN PHARMACEUTICAL CO LTD·Filed 2007·Granted Aug 30, 2011·0 cites·95 claims
- 1361US12290497B2Agent containing 4-phenylbutyrate, for preventing or treating presbyopiaSANTEN PHARMACEUTICAL CO LTD·Filed 2019·Granted May 6, 2025·0 cites·6 claims
- 1457US8580784B2Method for treating a disease related to the glucocorticoid receptorMATSUDA MAMORU·Filed 2011·Granted Nov 12, 2013·0 cites·7 claims
- 1557US8440660B2Method for treating a disease related to the glucocorticoid receptorMATSUDA MAMORU·Filed 2011·Granted May 14, 2013·0 cites·9 claims
- 1656US8563551B2Method for preventing or treating a disease related to the glucocorticoid receptorMATSUDA MAMORU·Filed 2011·Granted Oct 22, 2013·0 cites·8 claims
- 1755US2023346744A1Sulfur-containing compound useful for treating or preventing presbyopiaSANTEN PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1853US2023190766A1Agent for treating myopia, preventing myopia and/or suppressing myopia progressionSANTEN PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1951US8975256B21,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activitySANTEN PHARMACEUTICAL CO LTD·Filed 2013·Granted Mar 10, 2015·0 cites·5 claims
- 2048US2014045842A1Method for treating an inflammatory disease by administering a 1,2,3,4-tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituentSANTEN PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 2146US8420635B2Method for preventing or treating a glucocorticoid receptor-related diseaseMATSUDA MAMORU·Filed 2011·Granted Apr 16, 2013·0 cites·34 claims
- 2246US2022151989A1Lipoic acid prodrugSANTEN PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2345US2021059997A1Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedropsUNIV FUKUI·Filed 2018·Application pending·0 cites
- 2440US2005009902A1Remedies for pruritusFiled 2002·Application pending·0 cites
- 2537US2008119498A1Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active IngredientKATO MASATOMO·Filed 2005·Application pending·0 cites
- 2635US11642350B2Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredientSINGAPORE HEALTH SERV PTE LTD·Filed 2018·Granted May 9, 2023·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Masatomo Kato files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →